Cubist expects that Merrem I.V. will bring roughly $20 million in annual sales.
Cubist Pharmaceuticals will exclusively promote AstraZeneca’s antibiotic, Merrem® I.V., in the U.S. Cubist says that the agreement establishes a baseline of $20 million in annual revenues.
Merrem I.V. is indicated as a single-agent therapy for complicated appendicitis and peritonitis, complicated skin and skin structure infections, and pediatric bacterial meningitis, when caused by susceptible isolates of the indicated pathogens.
Cubist will promote and support Merrem I.V. using its existing U.S. acute-care sales and medical-affairs organizations. AstraZeneca will continue to provide marketing and commercial support for the product.
“As a broad-spectrum antibiotic, Merrem I.V. is an excellent fit with our gram-positive therapy, Cubicin, which has experienced the most successful I.V. antibiotic launch in U.S. history in dollar terms,” states evp and COO, Robert J. Perez.
